Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Current Leases (2019 - 2024)

Historic Current Leases for Kyntra Bio (KYNB) over the last 6 years, with Q3 2024 value amounting to $1.3 million.

  • Kyntra Bio's Current Leases fell 8911.98% to $1.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.3 million, marking a year-over-year decrease of 8911.98%. This contributed to the annual value of $12.6 million for FY2023, which is 2288.18% up from last year.
  • Kyntra Bio's Current Leases amounted to $1.3 million in Q3 2024, which was down 8911.98% from $15.5 million recorded in Q2 2024.
  • Kyntra Bio's Current Leases' 5-year high stood at $15.5 million during Q2 2024, with a 5-year trough of $1.3 million in Q3 2024.
  • Moreover, its 5-year median value for Current Leases was $11.5 million (2022), whereas its average is $11.3 million.
  • Data for Kyntra Bio's Current Leases shows a peak YoY increase of 5343.0% (in 2024) and a maximum YoY decrease of 8911.98% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Kyntra Bio's Current Leases stood at $12.3 million in 2020, then fell by 11.24% to $10.9 million in 2021, then decreased by 5.96% to $10.3 million in 2022, then rose by 22.88% to $12.6 million in 2023, then tumbled by 89.78% to $1.3 million in 2024.
  • Its Current Leases stands at $1.3 million for Q3 2024, versus $15.5 million for Q2 2024 and $15.2 million for Q1 2024.